|
1
|
Hernandez-Gea V, Toffanin S, Friedman SL
and Llovet JM: Role of the microenvironment in the pathogenesis and
treatment of hepatocellular carcinoma. Gastroenterology.
144:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Lope CR, Tremosini S, Forner A, Reig M
and Bruix J: Management of HCC. J Hepatol. 56:(Suppl 1). S75–S87.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spinzi G and Paggi S: Sorafenib in
advanced hepatocellular carcinoma. N Engl J Med. 359:2497–2498.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glackin CA: Targeting the Twist and Wnt
signaling pathways in metastatic breast cancer. Maturitas.
79:48–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noguchi K, Katayama K and Sugimoto Y:
Human ABC transporter ABCG2/BCRP expression in chemoresistance:
Basic and clinical perspectives for molecular cancer therapeutics.
Pharm Genomics Pers Med. 7:53–64. 2014.
|
|
6
|
Parasramka MA, Maji S, Matsuda A, Yan IK
and Patel T: Long non-coding RNAs as novel targets for therapy in
hepatocellular carcinoma. Pharmacol Ther. 161:67–78. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Birney E, Stamatoyannopoulos JA, Dutta A,
Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis
ET, Thurman RE, et al: Children's Hospital Oakland Research
Institute: Identification and analysis of functional elements in 1%
of the human genome by the ENCODE pilot project. Nature.
447:799–816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Derrien T, Johnson R, Bussotti G, Tanzer
A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG,
et al: The GENCODE v7 catalog of human long noncoding RNAs:
Analysis of their gene structure, evolution, and expression. Genome
Res. 22:1775–1789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Braconi C, Valeri N, Kogure T, Gasparini
P, Huang N, Nuovo GJ, Terracciano L, Croce CM and Patel T:
Expression and functional role of a transcribed noncoding RNA with
an ultraconserved element in hepatocellular carcinoma. Proc Natl
Acad Sci USA. 108:786–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Braconi C and Patel T: Non-coding RNAs as
therapeutic targets in hepatocellular cancer. Curr Cancer Drug
Targets. 12:1073–1080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
George J and Patel T: Noncoding RNA as
therapeutic targets for hepatocellular carcinoma. Semin Liver Dis.
35:63–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu D, Yang C, Bojdani E, Murugan AK and
Xing M: Identification of RASAL1 as a major tumor suppressor gene
in thyroid cancer. J Natl Cancer Inst. 105:1617–1627. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohta M, Seto M, Ijichi H, Miyabayashi K,
Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, et al:
Decreased expression of the RAS-GTPase activating protein RASAL1 is
associated with colorectal tumor progression. Gastroenterology.
136:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ngeow J and Eng C: RASAL1 in thyroid
cancer: Wisdom from an old foe. J Natl Cancer Inst. 105:1597–1599.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen H, Cheng Z-Y, Pan Y, Wang Z, Liu Y
and Zhang J-Q: RASAL1 influences the proliferation and invasion of
gastric cancer cells by regulating the RAS/ERK signaling pathway.
Hum Cell. 27:103–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kolfschoten IG, van Leeuwen B, Berns K,
Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM and Agami
R: A genetic screen identifies PITX1 as a suppressor of RAS
activity and tumorigenicity. Cell. 121:849–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Walker SA, Kupzig S, Bouyoucef D, Davies
LC, Tsuboi T, Bivona TG, Cozier GE, Lockyer PJ, Buckler A, Rutter
GA, et al: Identification of a Ras GTPase-activating protein
regulated by receptor-mediated Ca2+ oscillations. EMBO
J. 23:1749–1760. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loriot Y, Mordant P, Deutsch E, Olaussen
KA and Soria J-C: Are RAS mutations predictive markers of
resistance to standard chemotherapy? Nat Rev Clin Oncol. 6:528–534.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li W, Zhai B, Zhi H, Li Y, Jia L, Ding C,
Zhang B and You W: Association of ABCB1, β tubulin I, and III with
multidrug resistance of MCF7/DOC subline from breast cancer cell
line MCF7. Tumour Biol. 35:8883–8891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Febriansah R, Putri DD, Sarmoko Nurulita
NA, Meiyanto E and Nugroho AE: Hesperidin as a preventive
resistance agent in MCF-7 breast cancer cells line resistance to
doxorubicin. Asian Pac J Trop Biomed. 4:228–233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomayko MM and Reynolds CP: Determination
of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother
Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qiao F, Su X, Qiu X, Qian D, Peng X, Chen
H, Zhao Z and Fan H: Enforced expression of RASAL1 suppresses cell
proliferation and the transformation ability of gastric cancer
cells. Oncol Rep. 28:1475–1481. 2012.PubMed/NCBI
|
|
25
|
Villanueva A and Llovet JM: Second-line
therapies in hepatocellular carcinoma: Emergence of resistance to
sorafenib. Clin Cancer Res. 18:1824–1826. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhai B and Sun X-Y: Mechanisms of
resistance to sorafenib and the corresponding strategies in
hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang
X, Weng W, Pan Q, Yu Y, Sun F, et al: Tumor suppressor long
non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to
inhibit FoxA1 in liver cancer cells. Cell Signal. 26:2961–2968.
2014. View Article : Google Scholar : PubMed/NCBI
|
